Use of Alternative and Complementary Medicine by Colorectal Cancer Patients

NCT ID: NCT06779669

Last Updated: 2025-05-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

217 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-20

Study Completion Date

2025-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Complementary and alternative medicine (CAM) is defined by the National Center for Complementary and Alternative Medicine as "a group of diverse medical and health systems, practices and products that are not currently considered part of conventional medicine" (Complementary, Alternative, or Integrative Health, n. d. 2012). Complementary medicine is used to complement conventional medicine, and alternative medicine is used instead of conventional medicine (Dy et al., 2004). These are two very different approaches, whose consequences for a cancer patient can be completely different. The use of CAM is steadily increasing in most countries. A study carried out in France in 2017 revealed that for half of CAM users, the diagnosis of cancer was one of the main factors that led patients to turn to CAM (Sarradon-Eck et al., 2017). CAM use was found to be significantly associated with younger age, female gender and higher education (Sarradon-Eck et al., 2017). The source of information about MAC was mainly friends/family and the media, while doctors and nurses played a succinct role in MAC information (Molassiotis et al., 2005). The most frequently cited reasons for using CAM were to improve their physical well-being, strengthen their bodies, improve their emotional well-being and relieve the side effects of treatment (Sarradon-Eck et al., 2020). Another study carried out in 2019 at nine centers in France showed that 45% of glioma patients had changed their eating habits after glioma diagnosis, 44% were on complementary treatment, mainly vitamins and dietary supplements, and 32% were using alternative medicine, mainly magnetism and acupuncture. A total of 68% reported using at least one of these approaches (Le Rhun et al., 2019). Another single-center study conducted in France in 2019 found that 83% of cancer patients used CAM (M et al., 2019). CAM included osteopathy, homeopathy, acupuncture, therapeutic touch, magnetism, naturopathy, cupping, Chinese medicine, reflexology and hypnosis. However, no studies have been carried out to assess the use of CAM among colorectal cancer (CRC) patients in France.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Complementary and alternative medicine user

Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.

Group Type OTHER

Questionnaire CAM

Intervention Type OTHER

Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire CAM

Selected patients will answer a questionnaire about their practice and habits with regard to alternative and complementary medicines. Of these patients, 12 will also complete an additional qualitative questionnaire.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years of age
* Diagnosed with colorectal cancer
* To be operated on between 2017 and 2022

Exclusion Criteria

* The patient refuses to give consent to participate in the study
* Non-primary colorectal cancer (metastasis to the colon or rectum from another primary cancer; cancer originating in the appendix)
* Primary metastatic cancer other than colorectal cancer
* Discovery of cancer synchronous with colorectal cancer
* Guardianship or trusteeship
* Cognitive disorders (Alzheimer's, dementia, etc.)
* Severe psychiatric disorder (neurodevelopmental disorder, psychotic disorder, mood disorder, etc.) according to the specific DSM-5 and ICD-11 classifications
* Severe deafness (unable to answer questions during telephone interview)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Limoges

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Niki CHRISTOU, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Limoges

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

limoges University Hospital

Limoges, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

87RI24_0033 (ALTERNATIVCCR)

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.